GleamWall
中文EN

INVA Innoviva, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1080014 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.8%
TTM net income YoY51.9%
TTM EPS YoY41.6%
Revenue 3-yr CAGR14.7%
Net income 3-yr CAGR57.1%

Margins

Gross margin74.5%
Operating margin38.8%
Net margin44.1%
FCF margin41.6%
EBITDA margin—

Returns

ROE18.0%
ROA13.0%
ROIC (approx.)18.3%
Asset turnover0.30x

Leverage & solvency

Liabilities / assets26.0%
Debt / equity0.23x
Current ratio15.44x
Interest coverage8.64x

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio0.7%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue$106.12M$119.59M$97.99M$114.61M$107.80M$100.28M$88.63M$91.81M
Gross profit$84.38M$90.62M$75.83M$75.67M$75.54M$83.15M$73.31M$78.13M
R&D expense$5.21M$5.19M$5.24M$4.55M$13.67M$7.98M$4.40M$3.67M
SG&A expense$37.02M$34.57M$32.44M$32.12M$27.29M$26.41M$27.49M$31.33M
Operating income$42.15M$50.85M$38.15M$38.99M$34.58M$48.75M$41.43M$43.14M
Interest expense$5.47M$5.47M$5.44M$3.31M$4.01M$4.66M$4.71M$4.75M
Pretax income-$97.61M-$108.02M$234.56M$195.04M$97.82M$72.60M-$38.59M$24.69M
Income tax-$23.72M-$24.60M$47.97M$30.88M$7.91M$8.91M$8.00M$4.36M
Net income-$73.89M-$83.42M$186.59M$164.15M$89.91M$63.69M-$46.58M$20.33M
EPS (basic)-1.03-1.142.52—1.301.01-0.74—
EPS (diluted)-1.03-1.142.22—1.080.77-0.74—
Weighted avg. shares (diluted)72.07M73.42M84.85M—84.96M84.45M62.71M—
Balance sheet
Cash & equivalents$581.39M$570.39M$603.09M$550.94M$476.51M$397.53M$319.09M$304.96M
Inventory$42.84M$38.97M$38.84M$39.17M$38.36M$49.00M$41.48M$33.73M
Current assets$772.25M$753.37M$772.62M$727.51M$684.57M$651.78M$582.02M$554.31M
PP&E, net$2.04M$2.13M$2.14M$1.55M$1.53M$451,000$483,000$514,000
Goodwill$17.91M$17.91M$17.91M$17.91M$17.91M$17.91M$17.91M$17.91M
Intangibles$162.28M$168.98M$175.60M$182.16M$188.79M$195.41M$201.96M$208.43M
Total assets$1.54B$1.70B$1.84B$1.64B$1.43B$1.33B$1.25B$1.30B
Current liabilities$50.03M$47.06M$36.56M$49.70M$48.47M$246.56M$234.75M$236.08M
Short-term debt———$0$0$191.90M$192.22M$192.03M
Long-term debt$258.82M$258.45M$258.10M$257.73M$257.38M$257.02M$256.67M$256.32M
Total debt$258.82M$258.45M$258.10M$257.73M$257.38M$448.92M$448.88M$448.34M
Total liabilities$400.41M$469.46M$494.93M$462.32M$419.15M$618.75M$607.49M$609.90M
Shareholders' equity$1.14B$1.23B$1.34B$1.17B$1.01B$714.82M$646.90M$691.16M
Net debt-$322.57M-$311.93M-$344.99M-$293.21M-$219.14M$51.39M$129.79M$143.38M
Shares outstanding71.54M72.64M73.81M74.64M74.77M63.01M62.77M62.66M
Cash flow statement
Operating cash flow$41.70M$51.97M$35.28M$54.51M$49.73M$44.07M$48.62M$59.24M
Capital expenditure$24,000$429,000$492,000$10,000$1.12M$0$0$0
Free cash flow$41.67M$51.54M$34.79M$54.50M$48.61M$44.07M$48.62M$59.24M
Investing cash flow-$5.43M-$55.26M$37.01M$23.64M$18.41M$33.12M-$34.67M-$15.48M
Financing cash flow-$25.26M-$29.41M-$20.15M-$3.72M$10.84M$1.25M$183,000$573,000
Stock-based compensation$3.67M$4.74M$2.57M$2.50M$2.38M$2.42M$2.15M$1.67M
Share buybacks$26.07M$31.07M$20.25M$4.53M$0$0$0$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.